Trial Profile
A Randomized, Double-Blinded, Active-Controlled, Dose Ranging Study of CB-183,315 in Patients With Clostridium Difficile Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Surotomycin (Primary) ; Vancomycin
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- Sponsors Cubist Pharmaceuticals
- 12 Sep 2017 Results of a cohort of substudy (n=26) published in the Journal of Antimicrobial Chemotherapy
- 17 Jul 2016 Results published in the Journal of Antimicrobial Chemotherapy (2016).
- 20 Sep 2011 Results were reported at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy.